Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Bruce

Showing results (101-110 of 126) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2025
Investigating Early Kinetics in Plasma ctDNA and Peripheral T Cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck CancerEnrique Sanz-Garcia, Shirin Soleimani, Jeff P Bruce, et al.
Genome Medicine|November 2, 2018
Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivorsS Y Cindy Yang, Stephanie Lheureux, Katherine Karakasis, et al.
Cancer Discovery|July 12, 2022
AACR Project GENIE: 100,000 Cases and BeyondTrevor J Pugh, Jonathan L Bell, Jeff P Bruce, et al.
International Journal of Molecular Sciences|January 28, 2026
The Genetic and Molecular Analyses of Rare Candidate Germline <i>BRIP1/FANCJ</i> Variants Implicated in Hereditary Breast and Ovarian CancersWejdan M Alenezi, Larissa Milano, Caitlin T Fierheller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2023
Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor ProgressionStephanie Lheureux, Stephenie D Prokopec, Leslie E Oldfield, et al.
NPJ Vaccines|October 21, 2020
Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike proteinAlexander J McAuley, Michael J Kuiper, Peter A Durr, et al.
Frontiers in Immunology|June 3, 2022
At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron VariantNagendrakumar B Singanallur, Petrus Jansen van Vuren, Alexander J McAuley, et al.
Viruses|April 23, 2022
Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in MicePetrus Jansen van Vuren, Alexander J McAuley, Michael J Kuiper, et al.
Genes|February 25, 2023
Molecular Genetic Characteristics of <i>FANCI</i>, a Proposed New Ovarian Cancer Predisposing GeneCaitlin T Fierheller, Wejdan M Alenezi, Corinne Serruya, et al.
Nature Communications|August 30, 2024
FAM72A degrades UNG2 through the GID/CTLH complex to promote mutagenic repair during antibody maturationPhilip Barbulescu, Chetan K Chana, Matthew K Wong, et al.
Pageof 13

Showing results (101-110 of 126) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2025
Investigating Early Kinetics in Plasma ctDNA and Peripheral T Cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck CancerEnrique Sanz-Garcia, Shirin Soleimani, Jeff P Bruce, et al.
Genome Medicine|November 2, 2018
Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivorsS Y Cindy Yang, Stephanie Lheureux, Katherine Karakasis, et al.
Cancer Discovery|July 12, 2022
AACR Project GENIE: 100,000 Cases and BeyondTrevor J Pugh, Jonathan L Bell, Jeff P Bruce, et al.
International Journal of Molecular Sciences|January 28, 2026
The Genetic and Molecular Analyses of Rare Candidate Germline <i>BRIP1/FANCJ</i> Variants Implicated in Hereditary Breast and Ovarian CancersWejdan M Alenezi, Larissa Milano, Caitlin T Fierheller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2023
Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor ProgressionStephanie Lheureux, Stephenie D Prokopec, Leslie E Oldfield, et al.
NPJ Vaccines|October 21, 2020
Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike proteinAlexander J McAuley, Michael J Kuiper, Peter A Durr, et al.
Frontiers in Immunology|June 3, 2022
At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron VariantNagendrakumar B Singanallur, Petrus Jansen van Vuren, Alexander J McAuley, et al.
Viruses|April 23, 2022
Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in MicePetrus Jansen van Vuren, Alexander J McAuley, Michael J Kuiper, et al.
Genes|February 25, 2023
Molecular Genetic Characteristics of <i>FANCI</i>, a Proposed New Ovarian Cancer Predisposing GeneCaitlin T Fierheller, Wejdan M Alenezi, Corinne Serruya, et al.
Nature Communications|August 30, 2024
FAM72A degrades UNG2 through the GID/CTLH complex to promote mutagenic repair during antibody maturationPhilip Barbulescu, Chetan K Chana, Matthew K Wong, et al.
Pageof 13